GDF-15

GDF-15

GDF-15 Informations sur la molécule

Molecule Name
Growth/differentiation factor 15
Alias de la molécule
GDF15,GDF-15,MIC-1,MIC1,NAG-1,PDF,PLAB,PTGFB,NRG-1
Drug Development Progress
Nombre de médicaments cliniques10
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 3 Clinical
Alias de la cible
Placental TGF-beta,GDF-15,MIC1,PTGFB,MIC-1,PLAB,NSAID-activated gene 1 protein,Growth Differentiation Factor 15,Non-Steroidal Anti-Inflammatory Drug-Activated Gene-1,Placental Bone Morphogenetic Protein,NRG-1,PDF,Growth/Differentiation Factor 15,Macrophage Inhibitory Cytokine-1,PTGF-Beta,NSAID-regulated gene 1 protein,GDF15,Prostate Differentiation Factor,Macrophage Inhibitory Cytokine 1,NAG-1,NSAID (Nonsteroidal Anti-Inflammatory Drug)-Activated Protein 1
Contexte de la molécule
Growth Differentiation Factor 15 (GDF-15), also called Macrophage Inhibitory Cytokine 1 (MIC-1). Expression of MIC-1 mRNA in monocytoid cells is up-regulated by a variety of stimuli associated with activation, including interleukin 1β, tumor necrosis factor α (TNF-α), interleukin 2, and macrophage colony-stimulating factor but not interferon γ, or lipopolysaccharide (LPS). It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk. Increased GDF-15 levels are associated with cardiovascular diseases such as hypertrophy, heart failure, atherosclerosis, endothelial dysfunction, obesity, insulin resistance, diabetes, and chronic kidney diseases in diabetes. Increased GDF-15 level is linked with the progression and prognosis of the disease condition.

GDF-15 Liste de produits

Species
  • Human(4)
  • Cynomolgus(1)
  • Mouse(1)
Tag
  • His Tag(3)
  • Fc Tag(1)
  • Fc Tag & Avi Tag(1)
  • His Tag & Avi Tag(1)
Host
  • E. coli(4)
  • HEK293(2)
Conjugate
  • Unconjugated(4)
  • Biotin-labeled(2)
Grade
  • RUO(6)
Low Endotoxin
  • Yes(2)
  • No(4)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
GDF-15
Human GDF-15 / MIC-1 Protein, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$395.00

100ug
GDF-15
HOTAvitag
GD5-H81Q3
Biotinylated Human GDF-15 / MIC-1 Protein, His,Avitag™
Human
E. coli
SDS-PAGE
ELISA

$360.00

25ug
GDF-15
Cynomolgus GDF-15 / MIC-1 Protein, His Tag, low endotoxin
Cynomolgus
E. coli
SDS-PAGE
ELISA

$395.00

100ug
GDF-15
Human GDF-15 / MIC-1 Protein, His Tag, low endotoxin (Mass Spec verified)
Human
E. coli
SDS-PAGE
ELISA

$435.00

100ug
GDF-15
Avitag
GD5-H82F9
Biotinylated Human GDF-15 / MIC-1 Protein, Avitag™, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
GDF-15
Mouse GDF-15 / MIC-1 Protein, His Tag
Mouse
E. coli
SDS-PAGE
ELISASPR

$395.00

100ug
You Have Viewed 1-6 Of 6 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Plateforme de commerce de projets d'anticorps

Nom du projetPhase du projetType de moléculeSource de moléculeDomain thérapeutiqueIndication
GDF15 mAb - 01PCCMonoclonalHumanized MouseMetabolismSolid tumor,Cancer cachexia
Nom du projet
GDF15 mAb - 01
Phase du projet
PCC
Type de molécule
Monoclonal
Source de molécule
Humanized Mouse
Domain thérapeutique
Metabolism
Indication
Solid tumor,Cancer cachexia
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
VisugromabCTL-002Phase 3 ClinicalCatalYm GmbH
Cachexia; Carcinoma, Non-Small-Cell Lung; Solid tumours; Urinary Bladder Neoplasms
Details
PonsegromabPF-06946860Phase 3 ClinicalPfizer Inc
Anorexia; Breast Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Fatigue; Feeding and Eating Disorders; Heart Failure; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms
Details
NGM-120NGM-120Phase 2 ClinicalNGM Biopharmaceuticals Inc
Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Hyperemesis Gravidarum; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
GDF15 agonist (Lilly)Phase 1 ClinicalEli Lilly And Company
Diabetes Mellitus
Details
NN-9215Human-GDF15; MIC-1; NN-9215; LA-GDF15Phase 1 ClinicalNovo Nordisk A/S
Obesity
Details
GFS-202-AGFS-202-A; GFS202APhase 1 ClinicalGenfleet Therapeutics (Shanghai) Co Ltd
Cachexia
Details
GB-18GB-18; GB18Phase 1 ClinicalShandong Kexing Bio-Products Co Ltd
Cachexia
Details
CIN-109CIN-109; JNJ-9090Phase 1 ClinicalJanssen Sciences Ireland Unlimited Company
Obesity
Details
MBL-949MBL-949Phase 1 ClinicalNovartis Pharma Ag
Diabetes Mellitus; Obesity
Details
AV-380AV-380Phase 1 ClinicalAveo Pharmaceuticals Inc
Cachexia
Details
Customer Reviews